EurekaMag.com logo
+ Site Statistics
References:
53,623,987
Abstracts:
29,492,080
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Treatment of active CMV infection with oral ganciclovir in renal allograft recipients Monitoring efficacy with quantitative CMV-PCR



Treatment of active CMV infection with oral ganciclovir in renal allograft recipients Monitoring efficacy with quantitative CMV-PCR



Journal of the American Society of Nephrology 11(Program and Abstract Issue): 719A-720A, September




(PDF 0-2 workdays service: $29.90)

Accession: 035980726

Download citation: RISBibTeXText



Related references

Treatment of active CMV infection in renal allograft recipients with oral ganciclovir Monitoring efficacy using quantitative CMV-PCR. Journal of Investigative Medicine 49(1): 48A, January, 2001

Treatment of active cytomegalovirus disease with oral ganciclovir in renal allograft recipients: monitoring efficacy with quantitative cytomegalovirus polymerase chain reaction. American Journal of Transplantation 2(7): 671-673, 2002

Efficacy of early treatment of cytomegalovirus infection by ganciclovir in renal transplant recipients. Transplantation Proceedings 22(4): 1813-1814, 1990

Successful use of oral ganciclovir for the treatment of intrauterine cytomegalovirus infection in a renal allograft recipient. Transplant Infectious Disease 7(2): 71-74, 2005

Ganciclovir for cytomegalovirus cmv infection in renal allograft recipients. Journal of Urology 145(4 SUPPL): 304A, 1991

The efficacy of oral versus intravenously administered ganciclovir in the pre-emptive treatment of cytomegalovirus antigenemia in renal transplant recipients. Journal of the American Society of Nephrology 12(Program and Abstract Issue): 920A, September, 2001

Ganciclovir for invasive cytomegalovirus infection in renal allograft recipients. Transplantation Proceedings 23(1 Pt 2): 1346-1347, 1991

Impact of ganciclovir prophylaxis on CMV infection in cadaveric renal allograft recipients. Journal of the American Society of Nephrology 5(3): 1032, 1994

Hyperimmunoglobulin prophylaxis, monitoring and preemptive ganciclovir treatment eliminate the risk of CMV infection to improve patient and renal allograft survival. Transplant International 13 Suppl 1: S354-S358, 2000

Therapeutic use of ganciclovir for invasive cytomegalovirus infection in cadaveric renal allograft recipients. Journal of Urology 148(5): 1388-1392, 1992

Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. The Oral Ganciclovir International Transplantation Study Group [corrected. Lancet 350(9093): 1729-1733, 1997

Risk factors for cytomegalovirus disease in high risk renal allograft recipients under oral ganciclovir prophylaxis. Nephrology Dialysis Transplantation 16(6): A219, June, 2001

Late cytomegalovirus infection after oral ganciclovir prophylaxis in renal transplant recipients. Transplant Infectious Disease 6(1): 3-9, 2004

Detection of ganciclovir resistance after valacyclovir-prophylaxis in renal transplant recipients with active cytomegalovirus infection. Journal of Medical Virology 73(4): 566-573, 2004

A simplified strategy for clinical management of late cytomegalovirus infection after oral ganciclovir prophylaxis in renal recipients. Journal of Antimicrobial ChemoTherapy 55(3): 391-394, 2005